Unknown

Dataset Information

0

Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C.


ABSTRACT: AIMS:Drug-induced liver damage characterized by serum alanine aminotransferase (ALT) elevation often occurs in direct-acting antiviral (DAA) combination therapy for chronic hepatitis C virus (HCV) infection. This study explored single nucleotide polymorphisms (SNPs) at drug metabolism- or transport-related genes that were associated with ALT elevation in asunaprevir plus daclatasvir therapy. METHODS:Subjects were 185 Japanese patients with chronic HCV genotype 1b infection who received asunaprevir plus daclatasvir therapy. Tag SNPs at possible metabolizing enzyme and transporter genes, which were involved in the pharmacokinetics of asunaprevir and daclatasvir, were selected. RESULTS:Among the tag SNPs analyzed, CYP3A4 rs4646437 was significantly associated with ALT elevation (p = 0.013): maximum ALT values in patients with genotype CC were higher than those in patients with genotype non-CC (allele T). The proportion of grades 2-4 in genotype CC patients were significantly greater than those in genotype non-CC patients (p = 0.028). No patients with genotype non-CC showed grade ?2 ALT elevation. In multivariate analysis, rs4646437 genotype CC and cirrhosis were significant, independent factors associated with grade ?1 ALT elevation (odds ratio, 2.83 and 1.88; p = 0.040 and 0.045, respectively). In exploratory analyses, although serum concentrations of asunaprevir and daclatasvir were not correlated with maximum ALT values or rs4646437 genotypes, asunaprevir concentrations in patients with grade ?1 ALT elevation were significantly higher than those in patients with grade <1 ALT elevation (P = 0.023). CONCLUSIONS:CYP3A4 rs4646437 was found to be significantly and independently associated with ALT elevation in Japanese patients receiving ASV plus DCV therapy. Notably, none of the patients with rs4646437 genotype non-CC (allele T) had grade ?2 ALT elevation. SNP genotyping prior to treatment might be useful for carefully monitoring patients to complete treatment safely.

SUBMITTER: Kato K 

PROVIDER: S-EPMC6619746 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C.

Kato Keizo K   Shimada Noritomo N   Atsukawa Masanori M   Abe Hiroshi H   Itokawa Norio N   Matsumoto Yoshihiro Y   Agata Rie R   Tsubota Akihito A  

PloS one 20190710 7


<h4>Aims</h4>Drug-induced liver damage characterized by serum alanine aminotransferase (ALT) elevation often occurs in direct-acting antiviral (DAA) combination therapy for chronic hepatitis C virus (HCV) infection. This study explored single nucleotide polymorphisms (SNPs) at drug metabolism- or transport-related genes that were associated with ALT elevation in asunaprevir plus daclatasvir therapy.<h4>Methods</h4>Subjects were 185 Japanese patients with chronic HCV genotype 1b infection who rec  ...[more]

Similar Datasets

| S-EPMC5871831 | biostudies-literature
| S-EPMC4315868 | biostudies-literature
| S-EPMC6181393 | biostudies-literature
| S-EPMC5892899 | biostudies-literature
| S-EPMC4363215 | biostudies-literature
| S-EPMC4522028 | biostudies-literature
| S-EPMC5077083 | biostudies-literature
| S-EPMC6174986 | biostudies-literature
| S-EPMC6175176 | biostudies-literature
| S-EPMC6207024 | biostudies-literature